Provided by Tiger Trade Technology Pte. Ltd.

Immuneering Corp

5.62
0.0000
Volume:593.98K
Turnover:3.38M
Market Cap:362.88M
PE:-4.41
High:5.82
Open:5.64
Low:5.61
Close:5.62
52wk High:10.08
52wk Low:1.10
Shares:64.57M
Float Shares:54.41M
Volume Ratio:0.63
T/O Rate:1.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2729
EPS(LYR):-1.2729
ROE:-43.12%
ROA:-26.07%
PB:1.66
PE(LYR):-4.41

Loading ...

Immuneering Chief Scientific Officer Brett Matthew Hall Acquires Common Shares

Reuters
·
Jan 17

Top Immuneering Executive Makes Bold Move With Fresh Stock Purchase

TIPRANKS
·
Jan 16

Immuneering Chief People Officer Leah R. Neufeld Acquires Common Shares

Reuters
·
Jan 15

Immuneering Insider Makes Bold New Bet on Company’s Future

TIPRANKS
·
Jan 15

Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink

TIPRANKS
·
Jan 09

Immuneering Down Nearly 40%, on Pace for Largest Percent Decrease Since March 2024 -- Data Talk

Dow Jones
·
Jan 09

Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Benzinga
·
Jan 08

Stock Market Today: S&P 500, Dow Jones Futures Decline — AZZ, Northrop Grumman, Immuneering In Focus

Benzinga
·
Jan 08

Immuneering Corp (IMRX.US) Plunges 21% After-Hours Despite Pancreatic Cancer Therapy Outperforming Standard of Care, Lagging Behind Competitors

Stock News
·
Jan 08

Immuneering Reports 64% 12-Month Overall Survival in Phase 2a Pancreatic Cancer Trial

Reuters
·
Jan 08

Immuneering Announces Exceptional 64% Overall Survival at 12 Months in First-Line Pancreatic Cancer Patients Treated With Atebimetinib + Mgnp

THOMSON REUTERS
·
Jan 08

Immuneering Corp - to Dose First Patient in Phase 3 Trial Mid-2026

THOMSON REUTERS
·
Jan 08

Institutional investors control 36% of Immuneering Corporation (NASDAQ:IMRX) and were rewarded last week after stock increased 19%

Simply Wall St.
·
Dec 27, 2025

BRIEF-Immuneering To Announce 12-Month Overall Survival Data From Phase 2A Clinical Trial Of Atebimetinib + mGnP

Reuters
·
Dec 23, 2025

Immuneering to Announce 12-Month Survival Data from Phase 2a Pancreatic Cancer Trial

Reuters
·
Dec 23, 2025

Immuneering to Announce 12-Month Overall Survival Data From Phase 2a Clinical Trial of Atebimetinib + Mgnp in First-Line Pancreatic Cancer Patients on January 7, 2026

THOMSON REUTERS
·
Dec 23, 2025

BRIEF-Immuneering Advances Towards Dosing First Patient In Phase 3 Atebimetinib Trial

Reuters
·
Dec 18, 2025

Immuneering: Expects to Share Topline Results From Trial in Mid-2028

THOMSON REUTERS
·
Dec 18, 2025

Immuneering Expects to Dose First Patient in Global Phase 3 Registrational Trial, Mapkeeper 301, in Mid-2026

THOMSON REUTERS
·
Dec 18, 2025

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

GlobeNewswire
·
Dec 18, 2025